Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. AbbVie will pay ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...

Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders for ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after ...